Moderna Q3 Results: Raises Outlook on Vaccine Demand
Moderna Q3 results showed a revenue and profit beat and raised 2026 outlook on stronger vaccine demand, bolstering cash and prompting position flows.
KEY TAKEAWAYS
- Moderna reported Q3 revenue of $1.3 billion on stronger international COVID-19 vaccine sales and government partnership deliveries.
- The company raised 2026 revenue-growth guidance to 15%-25% from up to 10%, citing sustained vaccine demand.
- Year-end cash and investments were raised to $8.1-8.3 billion and GAAP operating expenses were cut by $200 million.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Moderna reported third-quarter 2026 revenue of $1.31 billion, a 29% increase year over year, driven by stronger international COVID-19 vaccine sales and deliveries under long-term government partnerships. The company swung to a GAAP net income of $162 million, or $0.38 per diluted share, from a net loss in the same quarter last year. These results prompted Moderna to raise its full-year revenue-growth outlook and upgrade its expected year-end cash position.
Third-Quarter Performance and Revenue Drivers
For the quarter ended September 30, 2026, Moderna’s revenue exceeded the Street average estimate of $885.1 million. U.S. revenue totaled $780 million, while international markets contributed $533 million. Management attributed the growth primarily to increased demand for COVID-19 vaccines overseas and deliveries under strategic government partnerships.
The company reported GAAP net income of $162 million, reversing a net loss of about $200 million, or $0.51 per share, in the third quarter of 2025. Moderna linked the profitability turnaround to the stronger vaccine sales and partnership deliveries.
Raised Outlook and Financial Position
Moderna raised its 2026 total-revenue growth forecast to 15%–25%, up from prior guidance of up to 10%. The company expects roughly half of its full-year revenue to come from the U.S. and half from international markets.
The company also increased its expected year-end cash and investments to approximately $8.1 billion–$8.3 billion, nearly doubling the previous guidance of $4.7 billion–$5.2 billion. Additionally, Moderna improved its 2026 GAAP operating-expense outlook by about $200 million, reflecting cost reductions.
The company linked the stronger outlook and larger cash balance to greater near-term financial flexibility for commercialization and pipeline programs.
Product Approvals and Pipeline Progress
The U.S. Food and Drug Administration approved Moderna’s mFLUSIVA, which the company described as its fifth approved product globally. Moderna also highlighted positive Phase 3 clinical trial results for intismeran, an investigational treatment for melanoma.
Executives cited newer products and broader geographic diversification as contributors to the quarter’s strength, supporting the raised revenue outlook and improved expense expectations.
